Entry17.17→Now18.45
OMER undervalued; Yartemla growth and Novo deal catalysts Open original source
OMER Omeros Corporation Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
23:43
Sep 15
Sep 15
OMER undervalued; Yartemla growth and Novo deal catalysts
The author argues Omeros is deeply undervalued, pointing to the CEO cutting 45% of debt and buying back 800,000 shares as signs of improving financial health. Yartemla sales are claimed to be expanding exponentially ($11M in Q1 to $33M in Q2), with NTAP and J-code approval beginning October 1st as a near-term reimbursement catalyst. A $2.1 billion deal with Novo Nordisk is said to include a near-term $100M payment, and Yartemla research into ARDs (a claimed 10x market) is expected to start by end of year. The author expects a 2x by end of year, with the main risk being reliance on these catalysts materializing as stated.
HIGH
About OMER Investor Commentary
Across the available history and selected sources, Buzzberg tracks OMER (Omeros Corporation) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Past 7 days, before deduplication: 1 bullish. Latest voices: u/Otherwise-Carrot-251.